427 related articles for article (PubMed ID: 25486307)
1. Targeting HIV-1 integrase with strand transfer inhibitors.
Li Y; Xuan S; Feng Y; Yan A
Drug Discov Today; 2015 Apr; 20(4):435-49. PubMed ID: 25486307
[TBL] [Abstract][Full Text] [Related]
2. Advances in the development of HIV integrase strand transfer inhibitors.
Wang Y; Gu SX; He Q; Fan R
Eur J Med Chem; 2021 Dec; 225():113787. PubMed ID: 34425310
[TBL] [Abstract][Full Text] [Related]
3. Structure and function of HIV-1 integrase.
Chiu TK; Davies DR
Curr Top Med Chem; 2004; 4(9):965-77. PubMed ID: 15134551
[TBL] [Abstract][Full Text] [Related]
4. A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores.
Kawasuji T; Yoshinaga T; Sato A; Yodo M; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8430-45. PubMed ID: 17010623
[TBL] [Abstract][Full Text] [Related]
5. Rational design of 2-pyrrolinones as inhibitors of HIV-1 integrase.
Ma K; Wang P; Fu W; Wan X; Zhou L; Chu Y; Ye D
Bioorg Med Chem Lett; 2011 Nov; 21(22):6724-7. PubMed ID: 21996518
[TBL] [Abstract][Full Text] [Related]
6. HIV integrase as a target for antiviral chemotherapy.
Nair V
Rev Med Virol; 2002; 12(3):179-93. PubMed ID: 11987143
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of HIV-1 integrase inhibitors--enzyme-ligand interactions.
Maurin C; Bailly F; Cotelle P
Curr Med Chem; 2003 Sep; 10(18):1795-810. PubMed ID: 12871105
[TBL] [Abstract][Full Text] [Related]
8. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis.
Xue W; Jin X; Ning L; Wang M; Liu H; Yao X
J Chem Inf Model; 2013 Jan; 53(1):210-22. PubMed ID: 23231029
[TBL] [Abstract][Full Text] [Related]
9. HIV integrase: a target for drug discovery.
Lutzke RA; Plasterk RH
Genes Funct; 1997 Dec; 1(5-6):289-307. PubMed ID: 17366700
[TBL] [Abstract][Full Text] [Related]
10. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors.
Kawasuji T; Fuji M; Yoshinaga T; Sato A; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8420-9. PubMed ID: 17005407
[TBL] [Abstract][Full Text] [Related]
11. Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain.
Molteni V; Greenwald J; Rhodes D; Hwang Y; Kwiatkowski W; Bushman FD; Siegel JS; Choe S
Acta Crystallogr D Biol Crystallogr; 2001 Apr; 57(Pt 4):536-44. PubMed ID: 11264582
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site.
Wielens J; Headey SJ; Jeevarajah D; Rhodes DI; Deadman J; Chalmers DK; Scanlon MJ; Parker MW
FEBS Lett; 2010 Apr; 584(8):1455-62. PubMed ID: 20227411
[TBL] [Abstract][Full Text] [Related]
13. Discovery of HIV-1 integrase inhibitors: pharmacophore mapping, virtual screening, molecular docking, synthesis, and biological evaluation.
Bhatt H; Patel P; Pannecouque C
Chem Biol Drug Des; 2014 Feb; 83(2):154-66. PubMed ID: 23957390
[TBL] [Abstract][Full Text] [Related]
14. Resistance to HIV-1 integrase inhibitors: A structural perspective.
Mouscadet JF; Delelis O; Marcelin AG; Tchertanov L
Drug Resist Updat; 2010; 13(4-5):139-50. PubMed ID: 20570551
[TBL] [Abstract][Full Text] [Related]
15. Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase.
Verschueren WG; Dierynck I; Amssoms KI; Hu L; Boonants PM; Pille GM; Daeyaert FF; Hertogs K; Surleraux DL; Wigerinck PB
J Med Chem; 2005 Mar; 48(6):1930-40. PubMed ID: 15771437
[TBL] [Abstract][Full Text] [Related]
16. Authentic HIV-1 integrase inhibitors.
Liao C; Marchand C; Burke TR; Pommier Y; Nicklaus MC
Future Med Chem; 2010 Jul; 2(7):1107-22. PubMed ID: 21426159
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.
Hazuda DJ; Felock P; Witmer M; Wolfe A; Stillmock K; Grobler JA; Espeseth A; Gabryelski L; Schleif W; Blau C; Miller MD
Science; 2000 Jan; 287(5453):646-50. PubMed ID: 10649997
[TBL] [Abstract][Full Text] [Related]
18. Study on the interactions between diketo-acid inhibitors and prototype foamy virus integrase-DNA complex via molecular docking and comparative molecular dynamics simulation methods.
Hu JP; He HQ; Tang DY; Sun GF; Zhang YQ; Fan J; Chang S
J Biomol Struct Dyn; 2013; 31(7):734-47. PubMed ID: 22913375
[TBL] [Abstract][Full Text] [Related]
19. Dissecting Tn5 transposition using HIV-1 integrase diketoacid inhibitors.
Czyz A; Stillmock KA; Hazuda DJ; Reznikoff WS
Biochemistry; 2007 Sep; 46(38):10776-89. PubMed ID: 17725323
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of 5-(1-H or 1-alkyl-5-oxopyrrolidin-3-yl)-8-hydroxy-[1,6]-naphthyridine-7-carboxamide inhibitors of HIV-1 integrase.
Melamed JY; Egbertson MS; Varga S; Vacca JP; Moyer G; Gabryelski L; Felock PJ; Stillmock KA; Witmer MV; Schleif W; Hazuda DJ; Leonard Y; Jin L; Ellis JD; Young SD
Bioorg Med Chem Lett; 2008 Oct; 18(19):5307-10. PubMed ID: 18774711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
